Notch Therapeutics Closes $85 Million Series A Financing

Ontario Industry Updates
Written By Maura Campbell
notch-logo.png

Notch Therapeutics Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced the closing of an oversubscribed U.S. $85 million Series A financing. Proceeds from the financing will support the continuing development of Notch’s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company’s proprietary Engineered Thymic Niche (ETN) platform.

Maura Campbell
Previous

OBIO Investment Summit Showcases Canada’s Booming Health Science Industry on the World Stage
Next

Microbix Introduces Viral Transport Medium